Loading
A phase 2/3 trial of cisplatin, gemcitabine and capecitabine in triple-negative breast cancer, run by Assiut University, not yet recruiting.
Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy is a phase 2/3, randomised interventional study registered as NCT06268327 by Assiut University, with a registry enrolment figure of 30 participants, started 2024-04-30 and due to reach its primary completion in 2025-10-30. Interventions recorded: Cisplatin injection and gemcitabine; Capecitabine tablets. Conditions listed: Breast Cancer. Triple-negative eligibility wording from the registry: "* Tumor subtype: triple negative". No results are recorded here; the registry entry is the source.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Cisplatin and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Gemcitabine and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Cytotoxic chemotherapy and the tag tnbc-deep-dive.